---
schema_version: "secwatch.filing_event.v1"
accession: "0001799191-24-000020"
form_type: "8-K"
ticker: "TOI"
cik: "0001799191"
company_name: "Oncology Institute, Inc."
filed_at: "2024-08-13T23:59:59+00:00"
generated_at: "2026-05-31T09:46:37.741069+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# TOI reports Q2 revenue $99M (+23% YoY), net loss $15.5M; exploring strategic alternatives

## Summary
- Q2 revenue $99M (+22.9% YoY); net loss $15.5M vs $16.9M prior year; EPS ($0.17).
- Gross profit $13M (-13.9%); gross margin 13.2% vs 18.8%; adjusted EBITDA ($8.7M) vs ($6.9M).
- Dispensary segment revenue up 76% YoY; 10 capitation contracts signed in 2024 so far.
- Company exploring strategic alternatives to maximize shareholder value.
- Cash $46.4M; full year 2024 guidance updated, expecting H2 improvement.

## SEC filing metadata
- accession: 0001799191-24-000020
- form_type: 8-K
- ticker: TOI
- cik: 0001799191
- company_name: Oncology Institute, Inc.
- filed_at: 2024-08-13T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1799191/000179919124000020/0001799191-24-000020-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1799191/000179919124000020/toi-20240813.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001799191-24-000020
- JSON: https://secwatch.observer/filing/0001799191-24-000020.json
- Plain text: https://secwatch.observer/filing/0001799191-24-000020.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.